KITTIPHONG THIBOONBOON is a research fellow at CHERE. His main responsibility is to provide critical appraisal for economic evaluations submitted to the Pharmaceutical Benefits Advisory Committee (PBAC). His main interest is using economic evaluation methods to support policymakers in the health care sector. He is experienced in modelling to evaluate the cost-effectiveness of health interventions and in performing systematic reviews. Prior to joining CHERE he was a researcher at the Health Intervention and Technology Assessment Program (HITAP) in Thailand where he provided technical assistance for projects in low- and middle-income countries, including health technology assessment, capacity strengthening and economic evaluation methodology research. He has a Bachelor’s degree in economics from Srinakharinwirot University, Thailand, and a Master’s degree in health economics from the University of York.
Bussabawalai, T, Thiboonboon, K & Teerawattananon, Y 2019, 'Cost-utility analysis of adjuvant imatinib treatment in patients with high risk of recurrence after gastrointestinal stromal tumour (GIST) resection in Thailand', Cost Effectiveness and Resource Allocation, vol. 17, no. 1.View/Download from: Publisher's site
© 2019 The Author(s). Background: Many patients develop tumour recurrence within a few years after undergoing surgical resection of gastrointestinal stromal tumours (GIST). Adjuvant imatinib treatment is recommended for patients with high risk of GIST recurrence as it can improve recurrence-free survival and overall survival of patients. This study aims to assess the cost-utility of adjuvant imatinib in patients with high risk of GIST recurrence after surgery compared with no adjuvant therapy in Thailand. Methods: A Markov model was developed to estimate lifetime costs and outcomes of using adjuvant imatinib treatment and other treatment alternatives if recurrence occurred compared with the current situation of no adjuvant therapy in high-risk patients after surgery. A 1-month cycle length was deployed in the model. Transition probabilities were derived from literature review. Costs were collected and calculated for the year 2014 from a societal perspective. Future costs and outcomes were discounted at 3% per year. One-way and probabilistic sensitivity analyses were conducted to assess parameter uncertainties. Results: Three years of adjuvant imatinib treatment followed by imatinib treatment and best supportive care if recurrence occurred after or during adjuvant therapy, respectively, was the best option as it produced more health outcomes (1.23 life years (LYs) and 1.16 quality-adjusted life years (QALYs)) compared to no adjuvant therapy while yielding the lowest incremental cost-effectiveness ratio (ICER) of 1,648,801 Thai Baht (THB) per QALY gained. Three years of adjuvant imatinib treatment followed by sunitinib treatment if recurrence occurred had an ICER of 2,608,264 THB per QALY gained compared to the best option, while other options were dominated. A one-way sensitivity analysis showed that the utility of patients receiving adjuvant imatinib had the greatest effect on the model, followed by the discount rate and probability of GIST recurrence. Conclusion...
Thiboonboon, K, Kulpeng, W & Teerawattananon, Y 2018, 'An economic analysis of chromosome testing in couples with children who have structural chromosome abnormalities', PLoS ONE, vol. 13, no. 6, pp. e0199318-e0199318.View/Download from: UTS OPUS or Publisher's site
Thiboonboon, K, Santatiwongchai, B, Chantarastapornchit, V, Rattanavipapong, W & Teerawattananon, Y 2016, 'A Systematic Review of Economic Evaluation Methodologies Between Resource-Limited and Resource-Rich Countries: A Case of Rotavirus Vaccines', Applied Health Economics and Health Policy, vol. 14, no. 6, pp. 659-672.View/Download from: Publisher's site
Thiboonboon, K, Leelahavarong, P, Wattanasirichaigoon, D, Vatanavicharn, N, Wasant, P, Shotelersuk, V, Pangkanon, S, Kuptanon, C, Chaisomchit, S & Teerawattananon, Y 2015, 'An economic evaluation of neonatal screening for inborn errors of metabolism using tandem mass spectrometry in Thailand', PLoS ONE, vol. 10, no. 8.View/Download from: Publisher's site
© 2015 Thiboonboon et al. Background: Inborn errors of metabolism (IEM) are a rare group of genetic diseases which can lead to several serious long-term complications in newborns. In order to address these issues as early as possible, a process called tandem mass spectrometry (MS/MS) can be used as it allows for rapid and simultaneous detection of the diseases. This analysis was performed to determine whether newborn screening by MS/MS is cost-effective in Thailand. Method: A cost-utility analysis comprising a decision-tree and Markov model was used to estimate the cost in Thai baht (THB) and health outcomes in life-years (LYs) and quality-adjusted life year (QALYs) presented as an incremental cost-effectiveness ratio (ICER). The results were also adjusted to international dollars (I$) using purchasing power parities (PPP) (1 I$ = 17.79 THB for the year 2013). The comparisons were between 1) an expanded neonatal screening programme using MS/MS screening for six prioritised diseases: phenylketonuria (PKU); isovaleric acidemia (IVA); methylmalonic acidemia (MMA); propionic acidemia (PA); maple syrup urine disease (MSUD); and multiple carboxylase deficiency (MCD); and 2) the current practice that is existing PKU screening. A comparison of the outcome and cost of treatment before and after clinical presentations were also analysed to illustrate the potential benefit of early treatment for affected children. A budget impact analysis was conducted to illustrate the cost of implementing the programme for 10 years. Results: The ICER of neonatal screening using MS/MS amounted to 1,043,331 THB per QALY gained (58,647 I$ per QALY gained). The potential benefits of early detection compared with late detection yielded significant results for PKU, IVA, MSUD, and MCD patients. The budget impact analysis indicated that the implementation cost of the programme was expected at approximately 2,700 million THB (152 million I$) over 10 years. Conclusion: At the current ceiling thresh...
Santatiwongchai, B, Chantarastapornchit, V, Wilkinson, T, Thiboonboon, K, Rattanavipapong, W, Walker, DG, Chalkidou, K & Teerawattananon, Y, 'Methodological Variation in Economic Evaluations Conducted in Low- and Middle-Income Countries: Information for Reference Case Development', PLOS ONE, vol. 10, no. 5, pp. e0123853-e0123853.View/Download from: Publisher's site